<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697593</url>
  </required_header>
  <id_info>
    <org_study_id>27809</org_study_id>
    <nct_id>NCT00697593</nct_id>
  </id_info>
  <brief_title>ChangE From Any Systemic psoriasiS therapY to Raptiva</brief_title>
  <acronym>EASY</acronym>
  <official_title>A Phase IV Open Label Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Transitioning From Previous Systemic Antipsoriasis Therapies (Methotrexate, Cyclosporine, Retinoids or Psoralen-Ultraviolet Light A (PUVA), Narrow-Band Ultraviolet Light B (NBUVB) to Raptiva 1mg/kg/ Week Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <brief_summary>
    <textblock>
      To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic
      or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or
      phototherapy dose.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated after the European Medicines Agency recommended to suspend the
    marketing authorisation of Raptiva in the European Union
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematology - Hematocrit</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Hemoglobin</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Red Blood Cell Count</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - White Blood Cell Count</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Neutrophils</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Eosinophils</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Basophils</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Monocytes</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Lymphocytes</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematology - Platelet Count</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Sodium</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Potassium</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Creatinine</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Total Bilirubin</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Aspartate Transaminase (AST)</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Alanine Transaminase (ALT)</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Alkaline Phosphatase</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Glutamyl Transferase</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - Urea</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemistry - C-Reactive Protein (CRP)</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Blood samples were taken for clinical laboratory testing of the numbers of participants with CRP values &lt;3 mg/L, 3-6 mg/L, and &gt;6 mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - pH</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Protein</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without protein in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Ketones</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without ketones in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Glucose</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without glucose in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Blood</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without blood in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Nitrite</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without nitrite in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis - Leukocytes Esterase</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without leukocytes esterase in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events, Serious Adverse Events, and Laboratory Data (Haematology and Biochemistry) and Urinalysis</measure>
    <time_frame>Week 12 / Early Termination</time_frame>
    <description>Information on adverse events are displayed in the adverse events section. Information laboratory data and urinalysis findings are displayed individually above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Static Physician's Global Assessment (sPGA)</measure>
    <time_frame>12 Weeks/Early Termination</time_frame>
    <description>Number of subjects who achieve an Static Physician's Global Assessment (sPGA) rating of clear; minimal; mild; moderate; severe; or very severe at Week 12 (Day 85).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Efalizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)</intervention_name>
    <description>Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.</description>
    <arm_group_label>Efalizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Are at least 18 years old.

          2. Have plaque psoriasis with an sPGA score of at least moderate or severe at time of
             initiation of previous systemic treatment.

          3. Are transitioning from methotrexate, cyclosporine, retinoids, PUVA or NBUVB and
             initiating treatment with Raptiva according to the decision of the investigator and in
             accordance with the indication and the recommendations of the Raptiva Investigator
             Brochure, i.e. to which they have failed to respond, have a contraindication to or are
             intolerant of other systemic therapies.

          4. Agree to participate in the study, and to disclose any medical events to the
             investigator. The subject must be willing and able to comply with the protocol
             requirements for the duration of the study.

          5. Have given written informed consent with the understanding that consent may be
             withdrawn at any time without prejudice to future medical care.

          6. Women of childbearing potential must use appropriate contraception during treatment
             and up to the last study visit (safety follow-up visit). For men, it is also mandatory
             to practice contraception during participation in the trial, as there are no existing
             data on the effect of Raptiva on spermatogenesis.

          7. Discontinuation of any investigational drug or treatment 3 months prior to study start
             or as per washout requirements from previous protocol.

        No primary vaccinations (e.g., tetanus, booster, influenza vaccine) for at least 14 days
        prior to first dose of study drug.For the purposes of this trial, women of childbearing
        potential is defined as: &quot;All female subjects after puberty unless they are post-menopausal
        for at least two years, are surgically sterile or are sexually inactive.&quot;

        Exclusion Criteria:

          1. Any contra-indication to Raptiva, according to the Investigator Brochure, or as
             follows:

               -  Hypersensitivity to Raptiva or to any of the excipients.

               -  Subjects with history of malignancies.

               -  History of active tuberculosis (TB) or currently undergoing treatment for TB.
                  Purified Protein Derivative (PPD) testing or chest X-ray is required for
                  high-risk subjects. Subjects with a positive PPD (not due to BCG vaccination) or
                  chest X-ray will be excluded.

               -  Subjects with specific forms of psoriasis like guttate, erythrodermic or pustular
                  psoriasis as sole or predominant form of psoriasis.

               -  Subjects with immunodeficiencies.

          2. Simultaneous participation in another clinical trial.

          3. Subjects experiencing a psoriasis exacerbation during screening period.

          4. Subjects who have previously been on Raptiva treatment who withdrew due to lack of
             efficacy or an adverse event. If withdrawal was due to another non-drug reason
             (vaccination, or infection) then the subject can be included in this study.

          5. History of hepatitis B, hepatitis C or human immunodeficiency virus (HIV).

          6. History of thrombocytopenia, haemolytic anaemia or clinically significant anaemia.

          7. Hepatic enzyme levels =/&gt;3 times the upper limit of normal or serum creatinine level
             =/&gt;2 times the upper limit of normal.

          8. Pregnant or breast-feeding.

          9. Any medical condition (prior or existing) that, in the judgment of the investigator or
             sponsor, could jeopardize the subject's safety following exposure to study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Selenko-Gebauer</last_name>
    <role>Study Director</role>
    <affiliation>Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Probity Medical Research</name>
      <address>
        <city>City Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>June 29, 2010</results_first_submitted>
  <results_first_submitted_qc>August 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2010</results_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2014</last_update_posted>
  <responsible_party>
    <name_title>Maria Koutsopoulou</name_title>
    <organization>Merck Serono International S.A., an affiliate of Merck KGaA, Darmstadt, Germany</organization>
  </responsible_party>
  <keyword>Efalizumab</keyword>
  <keyword>Chronic Plaque Psoriasis</keyword>
  <keyword>Transition from systemic therapies on to Efalizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of first subject first visit: 22 January 2008 Date of last subject last visit: 21 April 2009 Subjects were enrolled at 13 study centers in 2 countries, including 10 study centers in Canada and 3 study centers in the Netherlands.</recruitment_details>
      <pre_assignment_details>Subjects were to be screened for study eligibility within 14 days before Day 1</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Efalizumab</title>
          <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suspension of the study by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Efalizumab</title>
          <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 - 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>static Physician's Global Assessment (sPGA)</title>
          <description>Numbers of participants with sPGA ratings of clear; minimal; mild; moderate; severe; or very severe</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - C-Reactive Protein (CRP)</title>
          <description>Numbers of participants with CRP values &lt;3 mg/L, 3-6 mg/L, and &gt;6 mg/L</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants with &lt;3 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with 3 mg/L-6mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with &gt;6 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Alanine Transaminase (ALT)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.8" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Alkaline Phosphatase</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76.6" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Aspartate Transaminase (AST)</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Creatinine</title>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Glutamyl Transferase</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.9" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Potassium</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.19" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Values: Sodium</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Total Bilirubin</title>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.0" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biochemistry - Urea</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.677" spread="1.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Hematocrit</title>
          <units>packed cell volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.430" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Hemoglobin</title>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145.0" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Red Blood Cell Count</title>
          <units>x10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.69" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - White Blood Cell Count</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.11" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Basophils</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.032" spread="0.033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Eosinophils</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.177" spread="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Lymphocytes</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.911" spread="0.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Monocytes</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.462" spread="0.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Neutrophils</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.533" spread="1.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematology - Platelet Count</title>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256.0" spread="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Glucose</title>
          <description>Number of participants with or without glucose detected in urine</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Ketones</title>
          <description>Number of participants with or without ketones detected in urine</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Values - Nitrite</title>
          <description>Number of participants with or without nitrite detected in urine</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Leukocytes Esterase</title>
          <description>Number of participants with or without leukocytes esterase detected in urine</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Values - Protein</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - Blood</title>
          <description>Number of participants with or without blood detected in urine</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinalysis - pH</title>
          <units>pH units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.84" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Hematocrit</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 4 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Hematocrit</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 4 participants missing values</population>
          <units>packed cell volume</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.434" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Physician’s Global Assessment (sPGA)</title>
        <description>Number of subjects who achieve an Static Physician’s Global Assessment (sPGA) rating of clear; minimal; mild; moderate; severe; or very severe at Week 12 (Day 85).</description>
        <time_frame>12 Weeks/Early Termination</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Static Physician’s Global Assessment (sPGA)</title>
          <description>Number of subjects who achieve an Static Physician’s Global Assessment (sPGA) rating of clear; minimal; mild; moderate; severe; or very severe at Week 12 (Day 85).</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Hemoglobin</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Hemoglobin</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.8" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Red Blood Cell Count</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Red Blood Cell Count</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^12/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - White Blood Cell Count</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - White Blood Cell Count</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.06" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Neutrophils</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Neutrophils</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.047" spread="1.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Eosinophils</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Eosinophils</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Basophils</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Basophils</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Monocytes</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Monocytes</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.526" spread="0.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Lymphocytes</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Lymphocytes</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.209" spread="1.220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hematology - Platelet Count</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 4 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Hematology - Platelet Count</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 4 participants missing values</population>
          <units>x10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.5" spread="64.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Sodium</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Sodium</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Potassium</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Potassium</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.23" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Creatinine</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Creatinine</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Total Bilirubin</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Total Bilirubin</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Aspartate Transaminase (AST)</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 2 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Aspartate Transaminase (AST)</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 2 participants missing values</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Alanine Transaminase (ALT)</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Alanine Transaminase (ALT)</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Alkaline Phosphatase</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Alkaline Phosphatase</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Glutamyl Transferase</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Glutamyl Transferase</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - Urea</title>
        <description>Blood samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - Urea</title>
          <description>Blood samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 1 participant missing values</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.283" spread="1.628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Biochemistry - C-Reactive Protein (CRP)</title>
        <description>Blood samples were taken for clinical laboratory testing of the numbers of participants with CRP values &lt;3 mg/L, 3-6 mg/L, and &gt;6 mg/L</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 1 participant with missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemistry - C-Reactive Protein (CRP)</title>
          <description>Blood samples were taken for clinical laboratory testing of the numbers of participants with CRP values &lt;3 mg/L, 3-6 mg/L, and &gt;6 mg/L</description>
          <population>Safety Population - 1 participant with missing values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>participants with &lt;3 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with 3-6 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>participants with &gt;6 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - pH</title>
        <description>Urine samples were taken for clinical laboratory testing</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - pH</title>
          <description>Urine samples were taken for clinical laboratory testing</description>
          <population>Safety Population - 3 participants missing values</population>
          <units>pH units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Protein</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without protein in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Protein</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without protein in urine</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Ketones</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without ketones in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Ketones</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without ketones in urine</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Glucose</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without glucose in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants with missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Glucose</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without glucose in urine</description>
          <population>Safety Population - 3 participants with missing values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Blood</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without blood in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants with missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Blood</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without blood in urine</description>
          <population>Safety Population - 3 participants with missing values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Nitrite</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without nitrite in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants with missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Nitrite</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without nitrite in urine</description>
          <population>Safety Population - 3 participants with missing values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Urinalysis - Leukocytes Esterase</title>
        <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without leukocytes esterase in urine</description>
        <time_frame>Week 12 / Early Termination</time_frame>
        <population>Safety Population - 3 participants with missing values</population>
        <group_list>
          <group group_id="O1">
            <title>Efalizumab</title>
            <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis - Leukocytes Esterase</title>
          <description>Urine samples were taken for clinical laboratory testing of the number of participants with or without leukocytes esterase in urine</description>
          <population>Safety Population - 3 participants with missing values</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events, Serious Adverse Events, and Laboratory Data (Haematology and Biochemistry) and Urinalysis</title>
        <description>Information on adverse events are displayed in the adverse events section. Information laboratory data and urinalysis findings are displayed individually above</description>
        <time_frame>Week 12 / Early Termination</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <desc>'Other Adverse Events' table shows the number of participants experiencing any adverse event and the listing shows all treatment emergent adverse events occuring above the threshold value in the Safety Population</desc>
      <group_list>
        <group group_id="E1">
          <title>Efalizumab</title>
          <description>Each subject received an initial conditioning dose of efalizumab of 0.7 mg/kg/week and then was to continue treatment at a dose of 1 mg/kg/week for up to 12 weeks. Efalizumab was administered by subcutaneous injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sweat gland infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vascular occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Serono S.A., a division of Merck KGaA</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

